ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

Sanofi and Translate Bio to make mRNA vaccines for infectious diseases

by Ryan Cross
June 17, 2018 | APPEARED IN VOLUME 96, ISSUE 25

 

Sanofi Pasteur is paying $45 million up front to Lexington, Mass.-based Translate Bio, formerly known as RaNA Therapeutics, to develop messenger RNA (mRNA) vaccines for up to five infectious diseases. The vaccines could allow the body to use its own protein-making machinery to develop an immune response to the proteins translated from the mRNA. Translate could receive up to $760 million in additional milestone payments. Sanofi also has an ongoing partnership with BioNTech to develop cancer immunotherapies based on a similar mRNA technology.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment